Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 423.50M P/E - EPS this Y 31.70% Ern Qtrly Grth -
Income -159.13M Forward P/E -18.33 EPS next Y 38.40% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 40.24 EPS next 5Y - 52W High Chg -19.00%
Recommedations 1.70 Quick Ratio 0.87 Shares Outstanding 23.30M 52W Low Chg 106.00%
Insider Own 37.01% ROA -66.19% Shares Float 11.72M Beta 0.29
Inst Own 32.23% ROE - Shares Shorted/Prior 1.26M/1.33M Price 1.65
Gross Margin - Profit Margin - Avg. Volume 1,276,037 Target Price 39.91
Oper. Margin - Earnings Date Aug 12 Volume 1,001,706 Change -1.20%
About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics, Inc. News
05/17/24 Q2 2024 Outlook Therapeutics Inc Earnings Call
05/15/24 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
05/13/24 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
05/09/24 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
05/02/24 Outlook Therapeutics® to Present at the Retina World Congress 2024
04/29/24 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
04/26/24 Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors
04/15/24 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
04/15/24 Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
04/10/24 Insiders are Piling into These 10 Healthcare Stocks in 2024
03/22/24 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
03/18/24 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
03/12/24 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
03/06/24 7 of the Best Speculative Stocks You Can Snag for Less Than $1
02/25/24 7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
02/14/24 Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments
02/14/24 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
01/31/24 Outlook Therapeutics® Doses First Subject in NORSE EIGHT
01/24/24 Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
01/23/24 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
OTLK Chatroom

User Image Ang418 Posted - 3 hours ago

$OTLK things are gonna start getting interesting here this week 😉

User Image Britbox Posted - 17 hours ago

$OTLK is this one better? 😆

User Image Britbox Posted - 22 hours ago

$OTLK

User Image farcanal Posted - 1 day ago

$OTLK Five more trading days to wrap up and then it's Monday, May 27. Brussels timezone is 6 hours ahead of US ET so by 10am that day here we should probably have an idea of what has occurred there.

User Image Moneybags789 Posted - 1 day ago

$OTLK NICE!!

User Image _StockTrader Posted - 1 day ago

Real-Time Stock Data $OTLK Price: N/A Volume: N/A Market Cap: N/A PE Ratio: N/A Powered by: AITX

User Image RollingDollar Posted - 2 days ago

$OTLK

User Image GenerallyGentle Posted - 2 days ago

$OTLK $14 to $15 is my next short term target to the upside.

User Image GenerallyGentle Posted - 2 days ago

$OTLK Up $1 from yesterdays lows. Just doing my job (TA) reading the chart. Bullish AF

User Image Franca_ole Posted - 2 days ago

$OTLK Lytenava will be approved by the European Commission on May 27 at the latest and can then be marketed within the 27 member states: https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava $20 by the end of the year is not unrealistic!

User Image Saltytimtation Posted - 2 days ago

$OTLK my only problem is I don’t know how they are going to price it. Replacing something that was much cheaper for something that’s $500+ needs to show huge statistical dominance over the previous version for price hike to be justified.

User Image GenerallyGentle Posted - 2 days ago

$OTLK Muhahahah. THAT CLOSE at the HOD after a gap down and resulting in a bullish hammer. I hope you didnt get stopped out because that was a play to grab as much liquidity as possible before this takes off to the moon. Bullish AF now.

User Image Waldo_III Posted - 2 days ago

$OTLK BritBox posts/answers one of his many handles.. 😂😂😂😂🤡🤡🤡🤡🤡🤡🤡🤡

User Image GenerallyGentle Posted - 2 days ago

$OTLK Took above average energy to take it down this low today now it is getting bought back up and on target to create a bullish hammer. My honest opinion is this is getting ready for lift off real soon and they are checking for liquidity on this gap down. Any real sellers down here ? Looks like buyers to me. See you on the moon soon.

User Image EsquireTradingCo Posted - 2 days ago

$OTLK Those high 6s were so east but I couldn't double down. This stock cost me once already.

User Image Bobcatgoldfish Posted - 2 days ago

$OTLK going lower now because I bought more at $7

User Image Ang418 Posted - 3 days ago

$OTLK goddamnit where’s my cash when I need it I would be buying handover fist

User Image GenerallyGentle Posted - 3 days ago

$OTLK Tasty

User Image Britbox Posted - 3 days ago

$OTLK what suckers got stopped/scared out? Lessons learned soon enough

User Image sta120908 Posted - 3 days ago

$OTLK

User Image OTLKforecast Posted - 3 days ago

$OTLK Why? What about any of this? Did we not know what about any of this deserves a 10% dip?

User Image Multi_Millions Posted - 3 days ago

$OTLK oh I wish my money was available now and not at the end of next week! I’m throwing a few more thousands next week for sure!

User Image opportoni Posted - 3 days ago

$OTLK Those earnings were not received very well… I‘m officially a bagholder now. Fortunately not a big bag.

User Image AOMFAOU Posted - 3 days ago

$OTLK Oh and UK approval due Q3 this year

User Image AOMFAOU Posted - 3 days ago

$OTLK Listened to the call. 3mm potential shots in EU 50% will be lower priced choice which we will capture most if not all of. Pricing will be between $500 - $1000 a shot and they are leaning on the high side as competition raises prices. Anyone know the operating profit margin for a operation similar to ours? Contracted manuf + distro. Thanks

User Image GenerallyGentle Posted - 3 days ago

$OTLK We hit $7.50 zone folks and is about what I expected before news.

User Image opportoni Posted - 3 days ago

$OTLK Can anyone explain that change in fair value of warrant liabilities to me in easy terms?

User Image Britbox Posted - 3 days ago

$OTLK big buy after hours

User Image Buylocal Posted - 3 days ago

$OTLK lost more in a quarter than the stock is worth…

User Image Multi_Millions Posted - 3 days ago

$OTLK nothing to worry about IMO. We are still waiting for approval, that’s the next big catalyst

Analyst Ratings
HC Wainwright & Co. Buy May 17, 24
BTIG Buy Mar 27, 24
HC Wainwright & Co. Buy Mar 25, 24
Chardan Capital Buy Feb 15, 24
Guggenheim Buy Jan 25, 24
Brookline Capital Buy Jan 25, 24
Ascendiant Capital Buy Dec 29, 23
Capital One Overweight Dec 27, 23
HC Wainwright & Co. Buy Nov 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dagnon Terry Chief Operations Off.. Chief Operations Officer Apr 20 Sell 1.135 520,000 590,200 653,058 04/21/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 20 Sell 1.11 267,000 296,370 745,975 01/24/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 17 Sell 1.26 164,155 206,835 1,012,975 01/19/23
HILZINGER KURT J Director Director Oct 04 Buy 1.26 111,203 140,116 473,117 10/05/22
Dagnon Terry Chief Operating Offi.. Chief Operating Officer Jun 21 Buy 1.05 10,000 10,500 1,173,058 06/23/22
TRENARY C RUSSELL III CEO and President CEO and President Jun 21 Buy 1.06 19,925 21,120 54,925 06/23/22
HILZINGER KURT J Director Director Mar 01 Buy 1.69 27,708 46,827 273,117 03/03/22
HILZINGER KURT J Director Director Feb 24 Buy 1.53 47,160 72,155 245,409 02/28/22
HILZINGER KURT J Director Director Feb 22 Buy 1.47 175,132 257,444 198,249 02/23/22